DeCure for Salivary Gland Carcinoma ex Pleomorphic Adenoma
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Salivary Gland Carcinoma ex Pleomorphic Adenoma — screening already-approved drugs against its 36-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSalivary Gland Carcinoma ex Pleomorphic Adenoma maps to a 36-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for salivary gland carcinoma ex pleomorphic adenoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lysine demethylase 6A (KDM6A) — KDM6A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet e7zdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6FUL · 1.649 Å · ligand 1-methyl-5-oxidanyl-4-oxidanylidene-pyridine-2-carboxylic acid (E7Z). Experimental structure, not a prediction.
What the evidence adds up to
A retrospective review of 73 patients with major salivary gland carcinoma ex pleomorphic adenoma treated between 1960 and 1994 found that 55% died of the disease. Among 66 patients with primary tumours, 23% had local recurrence; regional metastasis occurred in 56% and distant metastasis in 44%. Overall survival was 39% at three years and 30% at five years. All patients were treated surgically, and 32 also received radiation therapy. Adenocarcinoma (31 cases) and salivary duct carcinoma (24 cases) were the most common malignant subtypes. The authors concluded that tumour size, grade, and clinical and pathologic stage were important prognostic factors, and that patients with minimally invasive tumours (less than 5 mm) should do well with appropriate surgical treatment.
A separate case report describes a clear cell carcinoma arising in a pleomorphic adenoma of a minor salivary gland, noting that malignant change in pleomorphic adenoma is uncommon, with a reported incidence of 2–10 per cent. Another report presents a single case of carcinoma ex pleomorphic adenoma of the upper lip in a 52-year-old woman, stating that this tumour comprises less than 4% of salivary gland neoplasms and 11.6% of salivary gland carcinomas, and that occurrence in minor salivary glands is rare.
One abstract reviews signalling pathways in salivary gland adenoid cystic carcinoma, a different tumour type, and does not address carcinoma ex pleomorphic adenoma. No drug treatments are mentioned in any of the abstracts.
What is still missing are prospective trials, any data on systemic therapy, and molecular stratification that might identify which patients with invasive disease could benefit from treatments beyond surgery and radiation.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Head & Neck · 2001 · 312 citations
Carcinoma ex pleomorphic adenoma: A clinicopathologic review
AbstractBACKGROUND: Carcinoma ex pleomorphic adenoma (CXPA) is an aggressive, poorly understood salivary gland malignancy. Misdiagnosis is common, because the residual mixed tumor component may be small, and various carcinoma subtypes are possible. METHODS: We retrospectively reviewed the medical records of 73 patients with major salivary gland CXPA treated at our institution from 1960 to 1994. Of the 73 patients, 66 had primary tumors and 7 had recurrent tumors; 47 were men, and 26 were women; the mean age was 61 years. RESULTS: Adenocarcinoma (31 cases) and salivary duct carcinoma (24 cases) were the most common malignant subtypes. All patients were treated surgically, and 32 also had radiation therapy. Of 66 patients with primary tumors, 23% had local recurrence. Metastasis (either initial or delayed) occurred regionally in 56% and distantly in 44%. Thirty-six patients (55%) died of the disease. At 3 years, overall survival was 39% and at 5 years, 30%. CONCLUSIONS: Important prognostic factors include tumor size, grade, and clinical and pathologic stage. Patients with minimally invasive tumors (<5 mm) should do well with appropriate surgical treatment.
The Journal of Laryngology & Otology · 1989 · 21 citations
Clear cell carcinoma arising in pleomorphic adenoma of the minor salivary gland
AbstractMalignant change arising in pleomorphic adenoma of the salivary glands is uncommon, with a reported incidence of 2-10 per cent. Only one case where a pleomorphic adenoma became a clear cell carcinoma appears to have been published in the English literature. An additional case of clear cell carcinoma arising in pleomorphic adenoma of a minor salivary gland is reported and the relevant literature discussed.
Research progress of signaling pathways mediating the proliferation, invasion and metastasis of salivary gland adenoid cystic carcinoma
AbstractSalivary gland adenoid cystic carcinoma is one of the most common malignant salivary gland tumors.Its invasion and metastasis are multi-stage and multifactorial processes,in which complex mechanisms and multiple signaling pathways are involved.Here,this article reviews the research progress in signaling pathways of salivary gland adenoid cystic carcinoma.
Key words:
Salivary adenoid cystic carcinoma; Signal path; Cell factor
World Journal of Dentistry · 2010 · 0 citations · open access
Carcinoma Ex Pleomorphic Adenoma of Upper Lip: An Unusual Presentation
AbstractABSTRACT Carcinoma ex-pleomorphic adenoma is a rare salivary gland malignancy, usually derived from a long-standing or recurrent benign tumor, the pleomorphic adenoma. 1 This rare tumor comprises less than 4% of salivary gland neoplasms and 11.6% of salivary gland carcinomas. They mostly involve the “major” salivary glands 1 and their occurrence in the minor salivary gland is considered rare, especially in the upper lip. So far there is only one report of CXPA occurring in the upper lip in the literature. 13 Hereby, we present a case of carcinoma ex-pleomorphic adenoma in a 52-year-old woman who reported to our department with a painful swelling on the upper lip which was diagnosed and treated successfully.
A case of carcinoma ex pleomorphic adenoma occurred in the sublingual gland
AbstractAbstract Carcinoma ex pleomorphic adenoma is a malignant salivary gland mixed tumor arising from an existing pleomorphic adenoma (PA). Less than 1% of cases occur in the sublingual gland. Salivary gland duct carcinomas (SDCs) also exhibit invasive development and are rarely found as a microinvasive lesion. A 47‐year‐old man complained of swelling of the oral floor during general dental treatment and was referred to our department. Excision was performed, and we histopathologically determined an early stage of SDC ex PA confirmed in the PA. Tumor from sublingual gland should be carefully treated in consideration of malignancy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
